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ST-elevation myocardial infarction (STEMI) is 
most commonly caused by the total occlu sion of 
an epicardial coronary artery by a thrombus. [1] 
The cornerstone of STEMI management is 
early re vascularisation, either by primary 
percutaneous coronary intervention or fibrinolytic therapy, in 
conjunction with other adjunctive pharmaceutical agents.[1] The 
most important determinant of outcome, irrespective of which 
form of revascularisation is selected, is the time from symptom 
onset to restoration of flow in the obstructed artery.[2] The ideal 
reperfusion strategy for STEMI is primary percutaneous coronary 
intervention (PCI), provided it is performed in an experienced 
centre within 90 minutes of the time of hospital arrival or arrival of 
the emergency medical services (EMS).[1] Fibrinolytic therapy should 
be administered as an alternative within 30 minutes, if primary PCI 
is unavailable or transport times exceed 60 minutes to the nearest 
centre capable of performing PCI.[1] Randomised controlled trials 
of fibrinolytic therapy have demonstrated the benefit of initiating 
fibrinolytic therapy as early as possible after the onset of angina.[3,4] 
A myocardial infarction may be aborted and mortality dramatically 
reduced if fibrinolytic therapy is administered within the first 2 
hours, and particularly within the first hour.[2]
Delays relating to patient factors, emergency service and transport 
factors, and in-hospital factors broadly account for the delays in 
provision of appropriate reperfusion therapy. Globally, numerous 
studies have demonstrated that significant delays exist in the provision 
of any reperfusion strategy, including fibrinolytic therapy, to patients 
presenting with STEMI.[5-10] The largest time delay is attributed to 
delays by the patient in seeking medical attention. Further delays 
occur following the call for help and relate to delays in transportation, 
as well as in-hospital delays.
In South Africa (SA) only a few tertiary public centres and selected 
private hospitals, almost exclusively in urban areas, are capable of 
performing primary PCI. The cardiology department at Steve Biko 
Academic Hospital (SBAH), Pretoria, was unable to perform routine 
primary PCI at the time of the study. Fibrinolytic therapy therefore 
constituted the primary revascularisation modality for patients 
presenting with STEMI. Furthermore, based on observation, few 
if any patients receive prehospital fibrinolytic therapy in SA, and 
there are minimal published data regarding the time to provision 
of fibrinolytic therapy (either prehospital or in-hospital). We 
therefore embarked on this study to systematically document the 
aforementioned observations in a tertiary hospital.
Objectives and methods
This prospective, observational study was performed over a 
14-month period between August 2008 and November 2009 at 
SBAH. The sample comprised 100 consecutive patients presenting 
to SBAH with STEMI. All patients with STEMI according to the new 
universal definition of myocardial infarction were included[11] unless 
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fibrinolytic therapy was contraindicated or 
primary PCI was performed. This study 
only addressed fibrinolytic therapy and 
not adjunctive agents such as aspirin. At 
the time of the study, SBAH was the only 
public tertiary referral hospital with a 
cardiology service for northern Gauteng 
and Mpumalanga provinces. Additionally, 
uninsured patients presenting to private 
hospitals were also referred to SBAH for 
further management. Patients at the time 
could not receive primary PCI or rescue 
PCI services, making timeous fibrinolytic 
administration essential.
Data in respect of demographics, timing 
of fibrinolytic therapy and reasons for 
delays in therapy were captured with the 
aid of a questionnaire. The questionnaire 
was personally administered by the first 
author during the hospital admission to 
reduce recall bias. Relevant information 
was also retrieved from the patients’ files, 
and via telephonic or personal interviews 
with the attending doctors where 
required. The total time delay between 
onset of symptoms and administration 
of fibrinolytic therapy was determined 
in minutes. Times were recorded to the 
nearest 5 minutes. A delay was defined as 
more than 60 minutes having elapsed from 
the time of symptom onset to the initiation 
of fibrinolytic therapy.[3] Only the data for 
patients receiving the medication within 
12 hours of onset of symptoms were 
analysed for in-hospital delays. However, 
these patients were included to analyse the 
prehospital delays.
The total time delay was then divided 
into: (i) patient factors – time from onset of 
symptoms to call for help: (ii) prehospital 
factors – time from call for help to arrival of 
help, and time from arrival of help to arrival 
at the hospital; and (iii) in-hospital factors  – 
door to assessment by a doctor, and time 
from assessment by a doctor to fibrinolytic 
therapy.
Potential reasons for delays were identified 
from the information obtained by the patient 
and patient record. Subsequently the impact 
of the delays in terms of loss of potential 
benefit (i.e. potential number of lives saved 
per thousand patients treated) was calculated 
from the above data.
Statistical analysis
All statistical analysis was performed 
using Matlab (version 7.1, MathWorks, 
USA). Categorical data were expressed as 
percentages. Continuous variables were 
expressed as means and standard deviations. 
Non-parametric data were expressed as 
medians and interquartile ranges.
The loss of absolute benefit for the sample, 
as a mean, was also calculated utilising 
the data from Boersma et al.[2] The benefit 
of fibrinolytic therapy was 65, 37, 26 and 
29 lives saved per 1 000 treated patients 
in the 0 - 1-, 1 - 2-, 2 - 3- and 3 - 6-hour 
intervals, respectively.[2] Based on the non-
linear regression equation f(x) = 19.4 − 
0.6x + 29.3x-1, the loss of absolute benefit 
per 1 000 patients treated, expressed as a 
percentage, is L(x) = 100(1 – f(x)/f(1)).[2] The 
loss of benefit relative to the first hour, as a 
percentage, can then be calculated as a mean 
for the 1 - 12-hour period. This value can 
be used to calculate the potential number of 
lives that could have been saved per 1 000 
patients treated for the 1 - 12-hour group, 
compared with the first hour (recalling that 
65 lives were saved per 1 000 patients treated 
in the first hour).[2]
Ethics
Ethics approval was granted by the Faculty of 
Health Sciences Ethics Committee, University 
of Pretoria. The study was conducted in accor -
dance with the Declaration of Helsinki.
Results
Baseline characteristics of the study patients 
are summarised in Table 1. The majority 
were white, male and had secondary level 
education. Seventy-three percent were 
employed. Fig. 1 outlines the referral course 
of the patients and the fibrinolytic therapy 
administration pattern. No patient received 
prehospital fibrinolytic therapy, and only 
37% of eligible patients received fibrinolytic 
therapy at all. Thirty-nine patients appro-
priately did not receive the medication, 
because of delayed presentation (10 at the 
presenting hospital and 29 at SBAH). Only 3 
patients received a fibrinolytic agent within 
1 hour, 34 did so between 1 and 12 hours, 
and 63 either did not receive a fibrinolytic 
therapy at all or received it after 12 hours. 
Table 2 summarises the mean treatment 
delays in minutes.
Prehospital delays
In respect of prehospital delays, the mean 
time from onset of symptoms to call for 
help was 35 minutes (range 5 - 1 185). Sixty 
patients called for help between 0 and 1 
hour, 33 between 1 and 12 hours, and 7 after 
12 hours. The last group were not candidates 
for fibrinolytic therapy.
The most common reason for delay 
(37%) was misinterpretation of symptoms as 
being non-cardiac in nature. Many patients 
(13%) adopted a wait-and-see approach, 
hoping that the symptoms would disappear 
spontaneously. Many of these patients 
reported that they were not aware of the 
importance or availability of receiving rapid 
treatment. Some also tried self-medicating 
(4%). Patients who had had a previous 
heart attack (3%) were likely to accurately 
recognise their symptoms as being a possible 
myocardial infarction and seek help sooner.
Patient location did not influence help-
seeking behaviour, except for patients who 
were driving. This latter group generally 
continued to their destination before seeking 
help.
Importantly, the vast majority (84%) of 
patients did not call for an ambulance at 
all, instead opting to use a private vehicle to 
reach the hospital, which was immediately 
available in 86% of cases.
The reasons cited for not calling an 
ambulance included ease of access and use 
of patients’ own transport, unfamiliarity 
with the emergency numbers, distrust of the 
emergency services (viewed as being slow, 
Table 1. Baseline characteristics
Age (years), mean (range) 52 (30 - 84)















Table 2. Summary of treatment delays 
(minutes), mean (range)
Onset of symptoms 
to call
35 (5 - 1 185)
Call to hospital 55 (12.5 - 670)
 Call to arrival of help 5 (5 - 20)
 Arrival of help to 
hospital
30 (10 - 435)
Door to fibrinolytic 62.5 (16.5 - 282)
Door to doctor 15 (0 - 654)
 Doctor to fibrinolytic 30 (10 - 258)
Total delay 270 (45 - 584)
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inefficient and occasionally not responding 
at all), lack of understanding concerning the 
potential risks (e.g. ventricular fibrillation) 
associated with a myocardial infarction 
and the ability of paramedics to treat these 
problems, and lack of understanding of the 
availability of and need for early treatment.
When patients did call for an ambulance, 
its late arrival, either due to the EMS being 
overburdened or to the driver getting lost, 
further contributed to delays in many cases. 
None of the patients who called for an 
ambulance received prehospital fibrinolytic 
therapy.
Ninety-one percent of patients who 
called for help accessed transport within 
1 hour. The majority of patients (76%) 
arrived at the first hospital within 1 hour. 
The most common reasons for delay were 
long distances travelled between the scene 
and the hospital, presenting to a general 
practitioner or clinic first (18%), and traffic 
delays. The majority (69%) of patients were 
driven to hospital in a private vehicle, 
while 14% drove themselves. Only 16% 
used an ambulance, and one patient walked 
to hospital.
In-hospital delays
A total of 38 patients were initially seen at 
primary or secondary level state hospitals, 
20 at private hospitals and 42 at SBAH. 
The 58 patients who initially presented to 
other hospitals took a median of 8 hours 
(range 1 - 288) to be transferred to SBAH. 
The median time from onset of symptoms 
to first medical contact was 135 minutes 
(range 20 - 1 400) or 2.3 hours (range 
0.3 - 23.3). Only 34 patients arrived within 
1 hour and 56 arrived between 1 and 12 
hours after symptom onset. Ten of the 
patients were only seen 12 hours after the 
onset of symptoms and were therefore not 
candidates for fibrinolytic therapy; they 
were excluded from the in-hospital analysis 
of delays. Overlapping reasons for delays 
were noted for each of the components 
evaluated.
Of patients seen at referral hospitals, 32 
(64%) were seen within 30 minutes. Only 4 
out of a potential 50 patients (8%) received 
a fibrinolytic agent, all within 20 minutes 
of seeing a doctor. Three patients received 
fibrinolytic agents in the emergency room 
and one in an intensive care unit. Three 
patients received streptokinase and one 
alteplase. Total delay from symptom onset 
to treatment was 45 minutes for 3 patients 
and 430 minutes for one patient. Generally, 
decisions on fibrinolytic administration were 
made by casualty officers following tele phonic 
consultation with an internal medicine 
registrar rotating through cardiology.
The most common reasons for delays in 
seeing a doctor were inappropriate triage 
with no priority given to patients with chest 
pain, waiting in queues to open folders prior 
to being evaluated, understaffing of hospitals 
with busy emergency rooms, and under-
resourced hospitals (electrocardiograph 
(ECG) machines were occasionally not 
working in some hospitals).
The most common reasons for delays 
in receiving fibrinolytic therapy were mis-
diagnosis of STEMI (including delays 
waiting for cardiac enzymes despite STEMI 
being obvious on the ECG or due to 
misinterpretation of the ECG), denial of 
fibrinolytic therapy on financial grounds 
in patients presenting to private hospitals, 
lack of familiarity with treatment protocols 
and inappropriate decision-making among 
attending doctors, especially inexperienced 
doctors, fear of complications, lack of 
urgency in administering the agents, absence 
of fibrinolytic agents in the emergency room 
or hospital, and late patient presentation 
(after 12 hours).
At SBAH 66 patients (83%) were seen 
within 30 minutes. The reasons for delays 
in being assessed by a doctor were similar 
to those in the presenting hospitals. Only 
58% of eligible patients received fibrinolytic 
agents within 12 hours. Twenty-seven 
patients received streptokinase while 5 
received alteplase. Seven patients were given 
fibrinolytic therapy after 12 hours and were 
not included in the analysis.
At SBAH, after assessment by a doctor, 
60% received a fibrinolytic agent within 1 
hour of assessment, with 41% receiving the 
medication after more than 1 hour. Twenty-
five patients received the fibrinolytic therapy 
in the emergency centre (EC), while 7 
received it in the coronary care unit (CCU). 
The median time delay between hospital 
arrival and arrival in the CCU was 420 
minutes (range 10 - 2 960). The door-to-
fibrinolytic time was a median of 60 minutes 
for those receiving the medication in the 
EC compared with 85 minutes for those 
receiving the medication in the CCU. The 
common reasons for delays in receiving 
fibrinolytic therapy were again similar to the 
other hospitals. Additionally, delayed referral 
from the presenting hospital contributed 
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Fig. 1. Flow diagram of fibrinolytic administration patterns. Only 37% of patients received fibrinolytic 
therapy within 12 hours.
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fibrinolytic was generally made by either 
the casualty officer or an internal medicine 
registrar rotating through cardiology. 
(Owing to staff constraints, not all STEMI 
patients could be seen immediately by a 
registrar in internal medicine.)
Fig. 2 summarises the loss of absolute 
benefit as a percentage (i.e. the preventable 
35-day mortality) for time delays beyond 1 
hour but less than 12 hours. An analysis was 
performed to determine the loss of absolute 
benefit as a mean for the sample by utilising 
the data from Boersma et al.[2] The mean 
loss of benefit as a percentage, relative to 
the first hour, for the 1 - 12-hour period is 
50.6%. This value was used to determine the 
additional number of lives that could have 
potentially been saved per 1 000 patients 
treated for the 1 - 12-hour group compared 
with the first hour. This value was 32/1 000. 
An additional 32 patients per 1 000 treated 
could therefore have been saved if the 
treatment had been administered within the 
first hour.
Discussion
The majority of patients in this study (67%) 
did not receive fibrino lytic therapy at all. 
Furthermore, the majority of those who 
did receive treatment received it late. A 
large number of eligible patients arrived at 
a facility capable of providing fibrinolytic 
therapy, but did not receive any treatment. 
These missed opportunities are clearly 
resulting in excess mortality and morbidity, 
including heart failure, which would 
otherwise be preventable.
Total treatment delays and the components 
of prehospital and in-hospital treatment 
delays were all prolonged in comparison 
with the international literature. The largest 
cumulative delays were experienced as a 
result of predominantly prehospital factors. 
With regard to patient factors, delayed time 
(>1 hour) from the onset of symptoms to call 
for help contributed significantly to delays 
in 40% of patients. The overriding reasons 
for these delays were lack of awareness of the 
symptoms of a myocardial infarction and 
how to respond appropriately and rapidly. 
This knowledge emphasises the importance 
of public awareness campaigns, as part of 
creating a STEMI network approach.
Of concern was that only 16 patients 
called for an ambulance, none of whom 
received prehospital fibrinolytic therapy. 
This represents an important opportunity 
for intervention by introducing paramedic 
training and certification to allow for 
prehospital fibrinolysis. Additionally, public 
awareness campaigns should focus on the 
risk of sudden death due to arrhythmias, 
which may be reduced by appropriately 
trained first responders. Patient perception 
of an inefficient EMS was also of concern. 
This may stem from the absence of a 
protocol-driven service, as well as poor 
resourcing, understaffing or poor training, 
although this requires further investigation. 
Integration of the EMS, including all first 
responders such as firemen and police 
officers, into the STEMI network would be 
crucial to its success. Staffing the receiving 
hospitals with full-time qualified staff to 
receive an ECG and then advise on therapy 
should become the standard of care. Having 
a clear plan regarding where to transport 
a patient within a given geographical area 
and the route of transportation is key. The 
geographical and financial constraints in SA 
dictate that early fibrinolytic therapy, ideally 
prehospital, would be the most efficient 
revascularisation strategy.
In-hospital delays, although not accounting 
for the greatest proportion of the total delay, 
were important because of the fact that the 
median door-to-fibrinolytic time was more 
than double the current recommendation 
of 30 minutes. Large numbers of eligible 
patients were denied therapy despite arrival 
within 12 hours. Common themes emerged 
when reasons for these delays were explored. 
These reflect practices that are contradictory 
to the current guidelines. The dominant 
problems were related to poor systems 
of care and staffing and, less commonly, 
lack of resources. Denying STEMI patients 
presenting to private hospitals fibrinolytic 
therapy cannot be justified at all, as this 
constitutes part of the emergency care of 
these patients as mandated by law. This again 
emphasises the need for protocol-driven care 
in the management of STEMI patients.
The impact of having no system of care is 
clear. The ubiquitous lack of urgency on 
the part of staff, reflecting lack of know-
ledge, being over-worked or simply apathy, 
was disturbing. Inappropriate triage and 
registration delays were almost universal 
because of the lack of dedicated chest pain 
units. Furthermore, the first attending 
doctor who was appropriately able to 
administer a fibrinolytic agent generally did 
not do so. This should clearly be done at 
the hospital to which the patient presented 
first. Inappropriate diagnosis and lack of 
familiarity with fibrinolytic therapy and the 
management of the complications associated 
with its administration may explain this 
behaviour. Furthermore, the perception by 
many casualty officers that administering 
fibrinolytics is ‘not their responsibility’ 
should be addressed. In this regard, 
cardiology consultation was often sought 
in unambiguous cases, rather than initiating 
appropriate treatment. These deficiencies 
can clearly be improved by implementing a 
STEMI network of care that integrates chest 
pain units at receiving hospitals.
Other opportunities for improvement 
were identified. These include not ordering 
un needed tests unless the diagnosis was 
clearly in question, and improving ECG 
interpretation skills in general. The 
introduction of bedside echocardiography 
could rapidly help to classify equivocal 
cases. However, this was seldom performed 
because of skills and equipment deficiencies. 
Interhospital transfer delays, while clearly 
problematic, could be mitigated if fibrino-
lytic agents were rapidly administered at the 
receiving hospital.
It is expected that public tertiary centres 

























Fig. 2. Loss of absolute benefit (%) v. treatment delay (hours).
RESEARCH
96       January 2016, Vol. 106, No. 1
Furthermore, based on personal observation, it is expected that many 
patients seen at the primary level of care are either missed or not 
appropriately referred at all. Owing to inappropriately constrained 
tertiary hospital capacity, patients are also frequently not accepted, 
although the exact numbers are difficult to estimate. Further research 
should be conducted in this regard.
Study limitations
This study represents the experience of a single tertiary centre. 
Referral bias is clearly a concern. Additionally, patients presenting 
after 12 hours were included in the study although they had presented 
late for fibrinolytic therapy. This was done in order to demonstrate 
the ‘real-world experience’ in SA and account for the reasons behind 
these patient delays. Other limitations were recall bias on the part 
of the patient and occasional lack of documentation of the times 
of in-hospital events in the notes. The EMS scene time, door-to-
ECG time and ECG-to-decision-to-give-fibrinolytic time were not 
routinely recorded in the available patient records.
Conclusion
Many patients failed to benefit from fibrinolytic therapy owing to a 
complete lack of fibrinolytic administration, delayed presentation 
and delayed therapy. This study highlights both the challenges and 
the opportunities that must be grasped in order to improve patient 
outcomes. Recognition of the seriousness and extent of this disease 
in the midst of numerous other healthcare priorities in SA is 
crucial. The authors encourage an urgent commitment to address 
these issues by all involved stakeholders. The implementation of 
a STEMI network, modified to local practice, is as possible as it 
is urgent.
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